The deficiency of the CDK inhibitors CDKN1B and CDKN2C has been associated with the presence of pituitary adenomas in murine models; CDKN1B and CDKN2C possibly control the function of Rb, working collaboratively to suppress pituitary tumorigenesis [32] and CDKN2C is frequently targeted by genomic alterations in pituitary adenomas [33]. Here, RB1 is linked to pituitary gland adenoma.